Inventiva (IVA) Current Deferred Tax Assets (2023 - 2024)
Inventiva's (IVA) quarterly Current Deferred Tax Assets came in at $2137.2 in Q4 2024, down 95.16% year-on-year from $44113.5 in Q1 2024, and down 0.77% quarter-over-quarter from $2153.8 in Q2 2024.
Inventiva (IVA) Current Deferred Tax Assets (2023 - 2024) Analysis & Trends
Inventiva's Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $2137.2 for Q4 2024.
- On a quarterly basis, Current Deferred Tax Assets fell 95.16% year-over-year to $2137.2 in Q4 2024; TTM through Dec 2024 was $2137.2, a 95.16% decrease from a year earlier, with the FY2024 full-year figure at $2137.2, down 95.16% from the prior year.
- Current Deferred Tax Assets slipped to $2137.2 in Q4 2024 per IVA's latest filing, from $2153.8 in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $44113.5 in Q4 2023 and bottomed at $2137.2 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,137.19 |
| Dec 31, 2024 | 2,137.19 |
| Jun 30, 2024 | 2,153.78 |
| Jun 30, 2024 | 2,153.78 |
| Dec 31, 2023 | 44,113.54 |
| Dec 31, 2023 | 44,113.54 |